Department of Ophthalmology, Wan Fang Hospital, Taipei Medical University, No. 111, Sec. 3, Xinglong Rd., Taipei 11696, Taiwan.
Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, No. 1, Jen Ai Road Sec. 1, Taipei 100, Taiwan.
Int J Mol Sci. 2021 Jul 5;22(13):7233. doi: 10.3390/ijms22137233.
Diabetic retinopathy (DR) is a common complication of diabetes that causes severe visual impairment globally. The pathogenesis of DR is related to oxidative stress and chronic inflammation. The fibroblast growth factor type 1 (FGF-1) mitogen plays crucial roles in cell function, development, and metabolism. FGF-1 is involved in blood sugar regulation and exerts beneficial antioxidative and anti-inflammatory effects on various organ systems. This study investigated the antioxidative and anti-inflammatory neuroprotective effects of FGF-1 on high-glucose-induced retinal damage. The results revealed that FGF-1 treatment significantly reversed the harmful effects of oxidative stress and inflammatory mediators in retinal tissue in a streptozotocin-induced diabetic rat model. These protective effects were also observed in the in vitro model of retinal ARPE-19 cells exposed to a high-glucose condition. We demonstrated that FGF-1 attenuated p38 mitogen-activated protein kinase and nuclear factor-κB pathway activation under the high-glucose condition. Our results indicated that FGF-1 could effectively prevent retinal injury in diabetes. The findings of this study could be used to develop novel treatments for DR that aim to reduce the cascade of oxidative stress and inflammatory signals in neuroretinal tissue.
糖尿病性视网膜病变(DR)是一种常见的糖尿病并发症,在全球范围内导致严重的视力损害。DR 的发病机制与氧化应激和慢性炎症有关。成纤维细胞生长因子 1 型(FGF-1)有丝分裂原在细胞功能、发育和代谢中发挥着重要作用。FGF-1 参与血糖调节,并对各种器官系统发挥有益的抗氧化和抗炎作用。本研究探讨了 FGF-1 对高糖诱导的视网膜损伤的抗氧化和抗炎神经保护作用。结果表明,FGF-1 治疗可显著逆转链脲佐菌素诱导的糖尿病大鼠模型中视网膜组织氧化应激和炎症介质的有害作用。在体外高糖培养的视网膜 ARPE-19 细胞模型中也观察到了这些保护作用。我们证明,FGF-1 可减轻高糖条件下 p38 丝裂原活化蛋白激酶和核因子-κB 通路的激活。我们的结果表明,FGF-1 可有效预防糖尿病性视网膜损伤。本研究的结果可用于开发新的 DR 治疗方法,旨在减少神经视网膜组织中氧化应激和炎症信号的级联反应。
Biomed Pharmacother. 2024-10
Prog Retin Eye Res. 2025-1
J Inflamm (Lond). 2024-2-23
World J Stem Cells. 2023-7-26
Biomolecules. 2023-3-28
Evid Based Complement Alternat Med. 2022-12-31
Front Endocrinol (Lausanne). 2020
Biochem Biophys Res Commun. 2020-7-23
Invest Ophthalmol Vis Sci. 2019-10-1
Curr Ophthalmol Rep. 2019-3
J Diabetes Res. 2019-8-14
Ann Anat. 2019-2-1
J Diabetes Res. 2018-9-23